Protagenic Therapeutics, Inc.
149 Fifth Avenue
New York, NY 10010
January 7, 2025
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
| Re: | Protagenic Therapeutics, Inc. Registration Statement on Form S-3 Originally filed June 14, 2024, as amended on January 7, 2025 File No. 333-280244 |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933 and on behalf of Protagenic Therapeutics, Inc. (the “Company”), the undersigned hereby requests that the Company’s Registration Statement on Form S-3 (File No. 333-280244) originally filed with the U.S. Securities and Exchange Commission (the “Commission”) on June 14, 2024, and amended on January 7, 2025 (the “Registration Statement”), be declared effective on January 8, 2025, at 5:00 pm, Eastern Standard Time, or as soon as practicable thereafter.
| Very truly yours, | ||
| PROTAGENIC THERAPEUTICS, INC. | ||
| By: | /s/ Alexander K. Arrow | |
Alexander K. Arrow Chief Financial Officer | ||
cc: Dean Colucci, Duane Morris LLP